ImmunityBio, Inc.
IBRX
Classement en actions
#2170
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Prix de l'action
$8.77
Capitalisation boursière
$9.29B
Changement (1 jour)
4.12%
Changement (1 an)
257.82%
Pays
US
Échange ImmunityBio, Inc. (IBRX)
Catégorie
Healthcare
Nombre d'actions en circulation pour ImmunityBio, Inc. (IBRX)
Nombre d'actions en circulation au June 2026: 1.05B
Selon les derniers rapports financiers et le cours de l'action de ImmunityBio, Inc., le nombre actuel d'actions en circulation est de 1.05B. À la fin de December 2023, l'entreprise avait 508.64M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de ImmunityBio, Inc. (IBRX) de 2013 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2026 (TTM) | 1.05B | 50.59% |
| 2024 | 697.31M | 37.09% |
| 2023 | 508.64M | 27.19% |
| 2022 | 399.90M | 2.74% |
| 2021 | 389.23M | 1.58% |
| 2020 | 383.18M | 0.00% |
| 2019 | 383.18M | 17.88% |
| 2018 | 325.05M | 2.81% |
| 2017 | 316.15M | -3.78% |
| 2016 | 328.55M | 0.69% |
| 2015 | 326.30M | 3.35% |
| 2014 | 315.73M | 0.00% |
| 2013 | 315.73M | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| 253.90M | -75.82% |
US
|
|
| 396.00M | -62.29% |
US
|
|
| 478.91M | -54.39% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -94.08% |
NL
|
